E. Van Essche

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial

Patrick Verschueren, Diederik De Cock, Luk Corluy et al. · Annals of the Rheumatic Diseases · 2014 · 124 citations · Full text

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial

Patrick Verschueren, Diederik De Cock, Luk Corluy et al. · Annals of the Rheumatic Diseases · 2016 · 114 citations

Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients

Kilian Verschueren, E. Van Essche, Patrick Verschueren et al. · Clinical Rheumatology · 2007 · 101 citations

Inflammation, Rheumatology, Rheumatoid Disorder +6

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

Patrick Verschueren, Diederik De Cock, Luk Corluy et al. · Arthritis Research & Therapy · 2015 · 42 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +7

Ultrasonographic, Axial, and Peripheral Measurements in Female Patients with Benign Hypermobility Syndrome

Jo Nijs, E. Van Essche, Maarten De Munck et al. · Calcified Tissue International · 2000 · 29 citations

Peripheral Measurements, Benign Hypermobility Syndrome, Diagnosis +5